Biota Holdings
Biota was an Australian antiviral drug development company listed on the Australian Stock Exchange (ASX:BTA).
In 1989, Biota discovered the drug Zanamivir, which acts as a neuraminidase inhibitor for the treatment and prevention of influenza. This drug is licensed to GlaxoSmithKline and marketed as Relenza.
In November 2012, Biota Holdings Limited merged with American company Nabi Biopharmaceuticals to form Biota Pharmaceuticals.
ATLANTA, 12 April 2016: Biota Pharmaceuticals, Inc. (NASDAQ:AVIR, formerly BOTA) today announced that the Company has changed its name to Aviragen Therapeutics, Inc., ("Aviragen Therapeutics"), a pharmaceutical company focused on the development of the next generation of direct-acting antivirals that address infections that have limited therapeutic options.
External links
| Stub icon | This article about an Australian corporation or company is a stub. You can help EverybodyWiki by expanding it. |
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help EverybodyWiki by expanding it. |
This article "Biota Holdings" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
